Vanda Pharmaceuticals Inc

Most Recent

  • uploads///Chart
    Company & Industry Overviews

    Insys Therapeutics: Recommendations and Market Capitalization

    Wall Street analysts estimate that INSY stock could decrease ~3% over the next 12 months. That show a 12-month target price of $9.60.

    By Mike Benson
  • uploads///nerve cell _
    Company & Industry Overviews

    Analysts’ Ratings for Alkermes and Its Peers in February 2018

    Of the 12 analysts covering Alkermes (ALKS) in February, five analysts gave ALKS a “buy” rating. Seven analysts gave it a “hold” rating.

    By Kenneth Smith
  • uploads///VNDA pipeline
    Company & Industry Overviews

    What Investors Can Expect from Vanda Pharmaceuticals in 2018

    Investors can expect a slew of critical developments from Vanda Pharmaceuticals (VNDA) in 2018.

    By Kenneth Smith
  • uploads///Hetlioz indications
    Company & Industry Overviews

    A Look at Vanda Pharmaceuticals’ Product Portfolio

    Vanda Pharmaceuticals’ (VNDA) Hetlioz was approved by the FDA in January 2014 for the treatment of Non-24-Hour Sleep Wake Disorder.

    By Kenneth Smith
  • uploads///virus _
    Company & Industry Overviews

    Analyst Ratings for Vanda Pharmaceuticals and Peers in February

    Of the six analysts covering Vanda Pharmaceuticals in February 2018, two of them have given the stock a “strong buy” rating.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.